Induced immunity against hepatitis B virus

World Journal of Hepatology

Volumn 7, Issue 12, 2015, Pages 1660-1670

  Ahmed Said, Zeinab Nabil ^a   Abdelwahab, Kouka Saadeldin ^a  

^a AL AZHAR UNIVERSITY   (Egypt)

Author keywords

Booster and therapeutic vaccination; Hepatitis B surface antigen; Hepatitis B virus; Hepatitis B virus vaccines; Immunological memory

Indexed keywords

EID: 84934282858     PISSN: None     EISSN: 19485182     Source Type: Journal    
DOI: 10.4254/wjh.v7.i12.1660     Document Type: Short Survey

References (92)

1. Blumberg BS, Alter HJ, Visnich S. A "new" antigen in leukemia sera. JAMA 1965; 191: 541-546 [PMID: 14239025 DOI: 10.1001/jama.1965.03080070025007].
2. Simmonds P, Midgley S. Recombination in the genesis and evolution of hepatitis B virus genotypes. J Virol 2005; 79: 15467-15476 [PMID: 16306618 DOI: 10.1128/JVI.79.24.15467-1 5476.2005].
3. Dane DS, Cameron CH, Briggs M. Virus-like particles in serum of patients with Australia-antigen-associated hepatitis. Lancet 1970; 1: 695-698 [PMID: 4190997].
4. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, Abraham J, Adair T, Aggarwal R, Ahn SY, Alvarado M, Anderson HR, Anderson LM, Andrews KG, Atkinson C, Baddour LM, Barker-Collo S, Bartels DH, Bell ML, Benjamin EJ, Bennett D, Bhalla K, Bikbov B, Bin Abdulhak A, Birbeck G, Blyth F, Bolliger I, Boufous S, Bucello C, Burch M, Burney P, Carapetis J, Chen H, Chou D, Chugh SS, Coffeng LE, Colan SD, Colquhoun S, Colson KE, Condon J, Connor MD, Cooper LT, Corriere M, Cortinovis M, de Vaccaro KC, Couser W, Cowie BC, Criqui MH, Cross M, Dabhadkar KC, Dahodwala N, De Leo D, Degenhardt L, Delossantos A, Denenberg J, Des Jarlais DC, Dharmaratne SD, Dorsey ER, Driscoll T, Duber H, Ebel B, Erwin PJ, Espindola P, Ezzati M, Feigin V, Flaxman AD, Forouzanfar MH, Fowkes FG, Franklin R, Fransen M, Freeman MK, Gabriel SE, Gakidou E, Gaspari F, Gillum RF, Gonzalez-Medina D, Halasa YA, Haring D, Harrison JE, Havmoeller R, Hay RJ, Hoen B, Hotez PJ, Hoy D, Jacobsen KH, James SL, Jasrasaria R, Jayaraman S, Johns N, Karthikeyan G, Kassebaum N, Keren A, Khoo JP, Knowlton LM, Kobusingye O, Koranteng A, Krishnamurthi R, Lipnick M, Lipshultz SE, Ohno SL, Mabweijano J, MacIntyre MF, Mallinger L, March L, Marks GB, Marks R, Matsumori A, Matzopoulos R, Mayosi BM, McAnulty JH, McDermott MM, McGrath J, Mensah GA, Merriman TR, Michaud C, Miller M, Miller TR, Mock C, Mocumbi AO, Mokdad AA, Moran A, Mulholland K, Nair MN, Naldi L, Narayan KM, Nasseri K, Norman P, O'Donnell M, Omer SB, Ortblad K, Osborne R, Ozgediz D, Pahari B, Pandian JD, Rivero AP, Padilla RP, Perez-Ruiz F, Perico N, Phillips D, Pierce K, Pope CA, Porrini E, Pourmalek F, Raju M, Ranganathan D, Rehm JT, Rein DB, Remuzzi G, Rivara FP, Roberts T, De León FR, Rosenfeld LC, Rushton L, Sacco RL, Salomon JA, Sampson U, Sanman E, Schwebel DC, Segui-Gomez M, Shepard DS, Singh D, Singleton J, Sliwa K, Smith E, Steer A, Taylor JA, Thomas B, Tleyjeh IM, Towbin JA, Truelsen T, Undurraga EA, Venketasubramanian N, Vijayakumar L, Vos T, Wagner GR, Wang M, Wang W, Watt K, Weinstock MA, Weintraub R, Wilkinson JD, Woolf AD, Wulf S, Yeh PH, Yip P, Zabetian A, Zheng ZJ, Lopez AD, Murray CJ, AlMazroa MA, Memish ZA. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380: 2095-2128 [PMID: 23245604 DOI: 10.1016/S0140-6736(12)61728-0].
5. World Health Organization. Global policy report on the prevention and control of viral hepatitis. In WHO Member States. [Accessed 2013 July]. Available from: URL: http://www.who.int/csr/disease/hepatitis/global_report/en/.
6. World Health Organization. Hepatitis B Fact sheet N°204. [Accessed 2015 March]. Available from: URL: http://www.who.int/mediacentre/factsheets/fs204/en/.
7. Lai M, Liaw YF. Chronic hepatitis B: past, present, and future. Clin Liver Dis 2010; 14: 531-546 [PMID: 20638030 DOI: 10.1016/j.cld.2010.05.003].
8. Ganem D, Prince AM. Hepatitis B virus infection-natural history and clinical consequences. N Engl J Med 2004; 350: 1118-1129 [PMID: 15014185 DOI: 10.1056/NEJMra031087].
9. Bertoletti A, Gehring AJ. The immune response during hepatitis B virus infection. J Gen Virol 2006; 87: 1439-1449 [PMID: 16690908 DOI: 10.1099/vir.0.81920-0].
10. Weber B. Genetic variability of the S gene of hepatitis B virus: clinical and diagnostic impact. J Clin Virol 2005; 32: 102-112 [PMID: 15653412 DOI: 10.1016/j.jcv.2004.10.008].
11. Obeng-Adjei N, Hutnick NA, Yan J, Chu JS, Myles DJ, Morrow MP, Sardesai NY, Weiner DB. DNA vaccine cocktail expressing genotype A and C HBV surface and consensus core antigens generates robust cytotoxic and antibody responses in mice and Rhesus macaques. Cancer Gene Ther 2013; 20: 652-662 [PMID: 24310062 DOI: 10.1038/cgt.2013.65].
12. Cova L. Advances and challenges in the development of therapeutic DNA vaccines against hepatitis B virus infection. Curr Gene Ther 2014; 14: 149-160 [PMID: 24828255 DOI: 10.2174/15 66523214666140509102644].
13. Heathcote EJ. Demography and presentation of chronic hepatitis B virus infection. Am J Med 2008; 121: S3-S11 [PMID: 19185072 DOI: 10.1016/j.amjmed.2008.09.024].
14. Ott JJ, Stevens GA, Wiersma ST. The risk of perinatal hepatitis B virus transmission: hepatitis B e antigen (HBeAg) prevalence estimates for all world regions. BMC Infect Dis 2012; 12: 131 [PMID: 22682147 DOI: 10.1186/1471-2334-12-131].
15. Centers for Disease Control and Prevention (CDC). The ABCs of Hepatitis Fact Sheet. [Updated 2014]. Available from: URL: http://www.cdc.gov/hepatitis/Resources/Professionals/PDFs/ABCTable.pdf.
16. Wright TL, Lau JY. Clinical aspects of hepatitis B virus infection. Lancet 1993; 342: 1340-1344 [PMID: 7694023 DOI: 10.1016/014 0-6736(93)92250-W].
17. Hoofnagle JH. Serologic markers of hepatitis B virus infection. Annu Rev Med 1981; 32: 1-11 [PMID: 7013654 DOI: 10.1146/annurev.me.32.020181.000245].
18. Yim HJ, Lok AS. Natural history of chronic hepatitis B virus infection: what we knew in 1981 and what we know in 2005. Hepatology 2006; 43: S173-S181 [PMID: 16447285 DOI: 10.1002/hep.20956].
19. Bertoletti A, Gehring A. Immune response and tolerance during chronic hepatitis B virus infection. Hepatol Res 2007; 37 Suppl 3: S331-S338 [PMID: 17931183 DOI: 10.1111/j.1872-034X.2007.00221.x].
20. Yang HI, Lu SN, Liaw YF, You SL, Sun CA, Wang LY, Hsiao CK, Chen PJ, Chen DS, Chen CJ. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med 2002; 347: 168-174 [PMID: 12124405 DOI: 10.1056/NEJMoa013215].
21. Fisicaro P, Valdatta C, Boni C, Massari M, Mori C, Zerbini A, Orlandini A, Sacchelli L, Missale G, Ferrari C. Early kinetics of innate and adaptive immune responses during hepatitis B virus infection. Gut 2009; 58: 974-982 [PMID: 19201769 DOI: 10.1136/gut.2008.163600].
22. Zhang ZH, Zhao XP, Xia JB, Li X, Lu MJ, Yang DL. [Characterization of HBsAbs in occult hepatitis B virus infection]. Zhonghua Gan Zang Bing Za Zhi 2011; 19: 506-510 [PMID: 22152241 DOI: 10.3760/cma.j.issn.1007-3418.2011.07.010].
23. Cheng PN, Tsai HW, Chiu YC, Ho CH, Wu IC, Chang TT. Clinical significance of serum HBsAg levels and association with liver histology in HBeAg positive chronic hepatitis B. J Clin Virol 2013; 57: 323-330 [PMID: 23731848 DOI: 10.1016/j.jcv.2013.04.012].
24. Fong TL, Di Bisceglie AM, Biswas R, Waggoner JG, Wilson L, Claggett J, Hoofnagle JH. High levels of viral replication during acute hepatitis B infection predict progression to chronicity. J Med Virol 1994; 43: 155-158 [PMID: 8083663 DOI: 10.1002/jmv.1890430210].
25. Guidotti LG, Rochford R, Chung J, Shapiro M, Purcell R, Chisari FV. Viral clearance without destruction of infected cells during acute HBV infection. Science 1999; 284: 825-829 [PMID: 10221919 DOI: 10.1126/science.284.5415.825].
26. Thimme R, Wieland S, Steiger C, Ghrayeb J, Reimann KA, Purcell RH, Chisari FV. CD8(+) T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection. J Virol 2003; 77: 68-76 [PMID: 12477811 DOI: 10.1128/JVI. 77.1.68-76.2003].
27. Murray PJ, Wynn TA. Protective and pathogenic functions of macrophage subsets. Nat Rev Immunol 2011; 11: 723-737 [PMID: 21997792 DOI: 10.1038/nri3073].
28. Wieland S, Thimme R, Purcell RH, Chisari FV. Genomic analysis of the host response to hepatitis B virus infection. Proc Natl Acad Sci USA 2004; 101: 6669-6674 [PMID: 15100412 DOI: 10.1073/pnas.0401771101].
29. Phillips S, Chokshi S, Riva A, Evans A, Williams R, Naoumov NV. CD8(+) T cell control of hepatitis B virus replication: direct comparison between cytolytic and noncytolytic functions. J Immunol 2010; 184: 287-295 [PMID: 19949099 DOI: 10.4049/jimmunol.0902761].
30. Stoop JN, van der Molen RG, Baan CC, van der Laan LJ, Kuipers EJ, Kusters JG, Janssen HL. Regulatory T cells contribute to the impaired immune response in patients with chronic hepatitis B virus infection. Hepatology 2005; 41: 771-778 [PMID: 15791617 DOI: 10.1002/hep.20649].
31. Penna A, Chisari FV, Bertoletti A, Missale G, Fowler P, Giuberti T, Fiaccadori F, Ferrari C. Cytotoxic T lymphocytes recognize an HLA-A2-restricted epitope within the hepatitis B virus nucleocapsid antigen. J Exp Med 1991; 174: 1565-1570 [PMID: 1720813 DOI: 10.1084/jem.174.6.1565].
32. Jiang M, Broering R, Trippler M, Poggenpohl L, Fiedler M, Gerken G, Lu M, Schlaak JF. Toll-like receptor-mediated immune responses are attenuated in the presence of high levels of hepatitis B virus surface antigen. J Viral Hepat 2014; 21: 860-872 [PMID: 24498958 DOI: 10.1111/jvh.1221].
33. Rehermann B, Fowler P, Sidney J, Person J, Redeker A, Brown M, Moss B, Sette A, Chisari FV. The cytotoxic T lymphocyte response to multiple hepatitis B virus polymerase epitopes during and after acute viral hepatitis. J Exp Med 1995; 181: 1047-1058 [PMID: 7532675 DOI: 10.1084/jem.181.3.1047].
34. Desmond CP, Gaudieri S, James IR, Pfafferott K, Chopra A, Lau GK, Audsley J, Day C, Chivers S, Gordon A, Revill PA, Bowden S, Ayres A, Desmond PV, Thompson AJ, Roberts SK, Locarnini SA, Mallal SA, Lewin SR. Viral adaptation to host immune responses occurs in chronic hepatitis B virus (HBV) infection, and adaptation is greatest in HBV e antigen-negative disease. J Virol 2012; 86: 1181-1192 [PMID: 22072755].
35. Lyseng-Williamson KA, Dhillon S. DTPa-HBV-IPV/Hib vaccine (Infanrix hexa™): a guide to its use in infants. Paediatr Drugs 2012; 14: 337-343 [PMID: 22873778 DOI: 10.2165/11210000-000 000000-00000].
36. Lavanchy D. Viral hepatitis: global goals for vaccination. J Clin Virol 2012; 55: 296-302 [PMID: 22999800 DOI: 10.1016/j.jcv.2012.08.022].
37. Mackie CO, Buxton JA, Tadwalkar S, Patrick DM. Hepatitis B immunization strategies: timing is everything. CMAJ 2009; 180: 196-202 [PMID: 19153395].
38. Centers for Disease Control and Prevention (CDC). Updated CDC recommendations for the management of hepatitis B virusinfected health-care providers and students. MMWR Recomm Rep 2012; 61: 1-12 [PMID: 22763928].
39. Michel ML, Tiollais P. Hepatitis B vaccines: protective efficacy and therapeutic potential. Pathol Biol (Paris) 2010; 58: 288-295 [PMID: 20382485 DOI: 10.1016/j.patbio.2010.01.006].
40. Romanò L, Paladini S, Galli C, Raimondo G, Pollicino T, Zanetti AR. Hepatitis B vaccination: are escape mutant viruses a matter of concern? Hum Vaccin Immunother 2015; 11: 53-57 [DOI: 10.4161/hv.34306].
41. West DJ, Calandra GB. Vaccine induced immunologic memory for hepatitis B surface antigen: implications for policy on booster vaccination. Vaccine 1996; 14: 1019-1027 [PMID: 8879096 DOI: 10.1016/0264-410X(96)00062-X].
42. Banatvala J, Van Damme P, Oehen S. Lifelong protection against hepatitis B: the role of vaccine immunogenicity in immune memory. Vaccine 2000; 19: 877-885 [PMID: 11115711 DOI: 10.1016/S0264-410X(00)00224-3].
43. Shouval D, Ilan Y, Adler R, Deepen R, Panet A, Even-Chen Z, Gorecki M, Gerlich WH. Improved immunogenicity in mice of a mammalian cell-derived recombinant hepatitis B vaccine containing pre-S1 and pre-S2 antigens as compared with conventional yeastderived vaccines. Vaccine 1994; 12: 1453-1459 [PMID: 7533967 DOI: 10.1016/0264-410X(94)90155-4].
44. Wolters B, Müller T, Ross RS, Clauberg R, Werfel U, Roggendorf H, Siggelkow C, Hausen T, Roggendorf M. Comparative evaluation of the immunogenicity of combined hepatitis A and B vaccine by a prospective and retrospective trial. Hum Vaccin 2009; 5: 248-253 [PMID: 19276678 DOI: 10.4161/hv.5.4.7051].
45. Shouval D. Hepatitis B vaccines. J Hepatol 2003; 39 Suppl 1: S70-S76 [PMID: 14708681 DOI: 10.1016/S0168-8278(03)00152-1].
46. Mahmood K, Pelkowski S, Atherly D, Sitrin RD, Donnelly JJ. Hexavalent IPV-based combination vaccines for public-sector markets of low-resource countries. Hum Vaccin Immunother 2013; 9: 1894-1902 [PMID: 23787559 DOI: 10.4161/hv.25407].
47. Nolan T, Lambert S, Roberton D, Marshall H, Richmond P, Streeton C. DTPa-HBV-IPV vaccine for primary vaccination of infants. J Paediatr Child Health 2007; 43: 587-592 [PMID: 17688642 DOI: 10.1111/j.1440-1754.2007.01139.x].
48. Shaw FE, Graham DJ, Guess HA, Milstien JB, Johnson JM, Schatz GC, Hadler SC, Kuritsky JN, Hiner EE, Bregman DJ. Postmarketing surveillance for neurologic adverse events reported after hepatitis B vaccination. Experience of the first three years. Am J Epidemiol 1988; 127: 337-352 [PMID: 2962488].
49. McMahon BJ, Helminiak C, Wainwright RB, Bulkow L, Trimble BA, Wainwright K. Frequency of adverse reactions to hepatitis B vaccine in 43,618 persons. Am J Med 1992; 92: 254-256 [PMID: 1532114 DOI: 10.1016/0002-9343(92)90073-K].
50. Zhang HZ, Wu WS, Su F, Sun CM, Jiang MB, Zhang GH, Wang XY, Xu ZY. [Valuation on the immunization efficacy on the 23 years who had received plasma-derived HBV vaccine as newborns]. Zhonghua Liuxingbingxue Zazhi 2012; 33: 207-209 [PMID: 22575145].
51. Shen L, Wang F, Wang F, Cui F, Zhang S, Zheng H, Zhang Y, Liang X, Bi S. Efficacy of yeast-derived recombinant hepatitis B vaccine after being used for 12 years in highly endemic areas in China. Vaccine 2012; 30: 6623-6627 [PMID: 22959987 DOI: 10.1016/j.vaccine.2012.08.067].
52. Neurath AR, Kent SB, Parker K, Prince AM, Strick N, Brotman B, Sproul P. Antibodies to a synthetic peptide from the preS 120-145 region of the hepatitis B virus envelope are virus neutralizing. Vaccine 1986; 4: 35-37 [PMID: 2421497 DOI: 10.1016/S0264-410X(86)80001-9].
53. Mancini-Bourgine M, Fontaine H, Scott-Algara D, Pol S, Bréchot C, Michel ML. Induction or expansion of T-cell responses by a hepatitis B DNA vaccine administered to chronic HBV carriers. Hepatology 2004; 40: 874-882 [PMID: 15382173 DOI: 10.1002/hep.20408].
54. Rottinghaus ST, Poland GA, Jacobson RM, Barr LJ, Roy MJ. Hepatitis B DNA vaccine induces protective antibody responses in human non-responders to conventional vaccination. Vaccine 2003; 21: 4604-4608 [PMID: 14575774 DOI: 10.1016/S0264-410X(03)00447-X].
55. Davis HL, McCluskie MJ, Gerin JL, Purcell RH. DNA vaccine for hepatitis B: evidence for immunogenicity in chimpanzees and comparison with other vaccines. Proc Natl Acad Sci USA 1996; 93: 7213-7218 [PMID: 8692971 DOI: 10.1073/pnas.93.14.7213].
56. Du DW, Jia ZS, Li GY, Zhou YY. HBV DNA vaccine with adjuvant cytokines induced specific immune responses against HBV infection. World J Gastroenterol 2003; 9: 108-111 [PMID: 12508362].
57. Wang J, Zhu R, Gao B, Wu B, Li K, Sun X, Liu H, Wang S. The enhanced immune response of hepatitis B virus DNA vaccine using SiO2@LDH nanoparticles as an adjuvant. Biomaterials 2014; 35: 466-478 [PMID: 24099705 DOI: 10.1016/j.biomaterials.2013.09.0 60].
58. Thanavala Y, Yang YF, Lyons P, Mason HS, Arntzen C. Immunogenicity of transgenic plant-derived hepatitis B surface antigen. Proc Natl Acad Sci USA 1995; 92: 3358-3361 [PMID: 7724566 DOI: 10.1073/pnas.92.8.3358].
59. Kapusta J, Modelska A, Figlerowicz M, Pniewski T, Letellier M, Lisowa O, Yusibov V, Koprowski H, Plucienniczak A, Legocki AB. A plant-derived edible vaccine against hepatitis B virus. FASEB J 1999; 13: 1796-1799 [PMID: 10506582].
60. Lou XM, Yao QH, Zhang Z, Peng RH, Xiong AS, Wang HK. Expression of the human hepatitis B virus large surface antigen gene in transgenic tomato plants. Clin Vaccine Immunol 2007; 14: 464-469 [PMID: 17314228].
61. Youm JW, Won YS, Jeon JH, Moon KB, Kim HC, Shin KS, Joung H, Kim HS. Antibody responses in mice stimulated by various doses of the potato-derived major surface antigen of hepatitis B virus. Clin Vaccine Immunol 2010; 17: 2029-2032 [PMID: 20943879].
62. Pniewski T, Kapusta J, Bociag P, Kostrzak A, Fedorowicz-Stronska O, Czyz M, Gdula M, Krajewski P, Wolko B, Plucienniczak A. Plant expression, lyophilisation and storage of HBV medium and large surface antigens for a prototype oral vaccine formulation. Plant Cell Rep 2012; 31: 585-595 [PMID: 22246107 DOI: 10.1007/s00299-011-1223-7].
63. Cobleigh MA, Buonocore L, Uprichard SL, Rose JK, Robek MD. A vesicular stomatitis virus-based hepatitis B virus vaccine vector provides protection against challenge in a single dose. J Virol 2010; 84: 7513-7522 [PMID: 20504927 DOI: 10.1128/JVI.00200-10].
64. Hong Y, Peng Y, Mi M, Xiao H, Munn DH, Wang GQ, He Y. Lentivector expressing HBsAg and immunoglobulin Fc fusion antigen induces potent immune responses and results in seroconversion in HBsAg transgenic mice. Vaccine 2011; 29: 3909-3916 [PMID: 21421003 DOI: 10.1016/j. vaccine.2011.03.025].
65. Song JM, Lee KH, Seong BL. Recombinant influenza viruses as delivery vectors for hepatis B virus epitopes. Clin Exp Vaccine Res 2012; 1: 77-82 [PMID: 23596580 DOI: 10.7774/cevr.2012.1.1.77].
66. Kwon SY, Lee CH. Epidemiology and prevention of hepatitis B virus infection. Korean J Hepatol 2011; 17: 87-95 [PMID: 21757978 DOI: 10.3350/kjhep.2011.17.2.87].
67. Chen SC, Toy M, Yeh JM, Wang JD, Resch S. Cost-effectiveness of augmenting universal hepatitis B vaccination with immunoglobin treatment. Pediatrics 2013; 131: e1135-e1143 [PMID: 23530168 DOI: 10.1542/peds.2012-1262].
68. Leuridan E, Van Damme P. Hepatitis B and the need for a booster dose. Clin Infect Dis 2011; 53: 68-75 [PMID: 21653306 DOI: 10.1093/cid/cir270].
69. Centers for Disease Control and Prevention (CDC). A comprehensive immunization strategy to eliminate transmission of hepatitis B virusinfection in the United States. Recommendations of the Advisory Committee on Immunization Practices (ACIP) Part 1: Immunization of Infants, Children, and Adolescents. Available from: URL: http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5416a1.htm.
70. Shaaban FA, Hassanin AI, Samy SM, Salama SI, Said ZN. Longterm immunity to hepatitis B among a sample of fully vaccinated children in Cairo, Egypt. East Mediterr Health J 2007; 13: 750-757 [PMID: 17955755].
71. Abushady EA, Gameel MM, Klena JD, Ahmed SF, Abdel-Wahab KS, Fahmy SM. HBV vaccine efficacy and detection and genotyping of vaccineé asymptomatic breakthrough HBV infection in Egypt. World J Hepatol 2011; 3: 147-156 [PMID: 21860674].
72. Gilca V, De Serres G, Boulianne N, De Wals P, Murphy D, Trudeau G, Massé R, Duval B. Antibody kinetics among 8-10 years old respondents to hepatitis B vaccination in a low endemic country and the effect of a booster dose given 5 or 10 years later. Vaccine 2009; 27: 6048-6053 [PMID: 19683086 DOI: 10.1016/j.vaccine.2009.07.100].
73. Salama II, Sami SM, Salama SI, Foud WA, Abdel Hamid AT, Said ZN. Persistence of protection to hepatitis B vaccine and response to booster dose among children and adolescents in Dakahleya-Egypt. Egypt J Immunol 2014; 21: 13-26 [PMID: 25204041].
74. Werner JM, Abdalla A, Gara N, Ghany MG, Rehermann B. The hepatitis B vaccine protects re-exposed health care workers, but does not provide sterilizing immunity. Gastroenterology 2013; 145: 1026-1034 [PMID: 23916846 DOI: 10.1053/j.gastro.2013.07.044].
75. Centers for Disease Control and Prevention (CDC). Immunization of health-care personnel: recommendations of the Advisory Committee on Immunization Practices (ACIP). [Accessed 2011 Nov 25]. Available from: URL: http://www.cdc.gov/mmwr/preview/mmwrhtml/rr6007a1.htm.
76. Centers for Disease Control and Prevention (CDC). A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices. Recommendations of the Advisory Committee on Immunization Practices (ACIP) Part II: immunization of adults. [Accessed, 2006 Dec 8]. Available from: URL: http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5516a1.htm.
77. Centers for Disease Control and Prevention (CDC). Recommended adult immunization schedule-United States-2015. Available from: URL: http://www.cdc.gov/vaccines/schedules/downloads/adult/adult-schedule.pdf.
78. Fitzsimons D, François G, Hall A, McMahon B, Meheus A, Zanetti A, Duval B, Jilg W, Böcher WO, Lu SN, Akarca U, Lavanchy D, Goldstein S, Banatvala J, Damme PV. Long-term efficacy of hepatitis B vaccine, booster policy, and impact of hepatitis B virus mutants. Vaccine 2005; 23: 4158-4166 [PMID: 15964484].
79. Poorolajal J, Mahmoodi M, Majdzadeh R, Nasseri-Moghaddam S, Haghdoost A, Fotouhi A. Long-term protection provided by hepatitis B vaccine and need for booster dose: a meta-analysis. Vaccine 2010; 28: 623-631 [PMID: 19887132 DOI: 10.1016/j.vaccine.2009.10.068].
80. Filippelli M, Lionetti E, Gennaro A, Lanzafame A, Arrigo T, Salpietro C, La Rosa M, Leonardi S. Hepatitis B vaccine by intradermal route in non responder patients: an update. World J Gastroenterol 2014; 20: 10383-10394 [PMID: 25132754 DOI: 10.3748/wjg.v20.i30.10383].
81. Grzegorzewska AE, Wobszal PM, Mostowska A, Jagodzinski PP. Antibodies to hepatitis B virus surface antigen and interleukin 12 and interleukin 18 gene polymorphisms in hemodialysis patients. BMC Nephrol 2012; 13: 75 [PMID: 22863216 DOI: 10.1186/1471-2369-13-75].
82. Middleman AB, Anding R, Tung C. Effect of needle length when immunizing obese adolescents with hepatitis B vaccine. Pediatrics 2010; 125: e508-e512 [PMID: 20142295 DOI: 10.1542/peds.2009-1592].
83. Liu J, Kosinska A, Lu M, Roggendorf M. New therapeutic vaccination strategies for the treatment of chronic hepatitis B. Virol Sin 2014; 29: 10-16 [PMID: 24452539 DOI: 10.1007/s12250-014-3410-5].
84. Couillin I, Pol S, Mancini M, Driss F, Bréchot C, Tiollais P, Michel ML. Specific vaccine therapy in chronic hepatitis B: induction of T cell proliferative responses specific for envelope antigens. J Infect Dis 1999; 180: 15-26 [PMID: 10353856 DOI: 10.1086/314828].
85. Akbar SM, Al-Mahtab M, Uddin MH, Khan MS. HBsAg, HBcAg, and combined HBsAg/HBcAg-based therapeutic vaccines in treating chronic hepatitis B virus infection. Hepatobiliary Pancreat Dis Int 2013; 12: 363-369 [PMID: 23924493].
86. Thermet A, Buronfosse T, Werle-Lapostolle B, Chevallier M, Pradat P, Trepo C, Zoulim F, Cova L. DNA vaccination in combination or not with lamivudine treatment breaks humoral immune tolerance and enhances cccDNA clearance in the duck model of chronic hepatitis B virus infection. J Gen Virol 2008; 89: 1192-1201 [PMID: 18420797 DOI: 10.1099/vir.0.83583-0].
87. Gaggar A, Coeshott C, Apelian D, Rodell T, Armstrong BR, Shen G, Subramanian GM, McHutchison JG. Safety, tolerability and immunogenicity of GS-4774, a hepatitis B virus-specific therapeutic vaccine, in healthy subjects: a randomized study. Vaccine 2014; 32: 4925-4931 [PMID: 25045824 DOI: 10.1016/j. vaccine.2014.07.027].
88. Michel ML, Bourgine M, Fontaine H, Pol S. Therapeutic vaccines in treating chronic hepatitis B: the end of the beginning or the beginning of the end? Med Microbiol Immunol 2015; 204: 121-129 [PMID: 25511871].
89. Kao JH, Chen DS. Global control of hepatitis B virus infection. Lancet Infect Dis 2002; 2: 395-403 [PMID: 12127351].
90. Lazarevic I. Clinical implications of hepatitis B virus mutations: recent advances. World J Gastroenterol 2014; 20: 7653-7664 [PMID: 24976703 DOI: 10.3748/wjg.v20.i24.7653].
91. Carman WF, Zanetti AR, Karayiannis P, Waters J, Manzillo G, Tanzi E, Zuckerman AJ, Thomas HC. Vaccine-induced escape mutant of hepatitis B virus. Lancet 1990; 336: 325-329 [PMID: 1697396].
92. Pollicino T, Cacciola I, Saffioti F, Raimondo G. Hepatitis B virus PreS/S gene variants: pathobiology and clinical implications. J Hepatol 2014; 61: 408-417 [PMID: 24801416 DOI: 10.1016/j.jhep.2014.04.041].